Pharmacy

After a slower year of merger and acquisition activity than expected in 2018, 2019 started off with a bang when Bristol-Myers Squibb agreed to buy Celgene for $74 billion in cash and stock — one of the largest deals in…

Aurobindo Pharma on Dec. 31 recalled 80 lots of the blood pressure drug valsartan after discovering trace amounts of a cancer-causing impurity in the products.

Molina Healthcare extended its contract with pharmacy benefit manager CVS Caremark through 2021, marking the first major win for CVS since its acquisition of Aetna.

Bristol-Myers Squibb plans to acquire cancer drugmaker Celgene for $74 billion in cash and stock — one of the largest deals in pharmaceutical history.

The U.S. Supreme Court will consider a case next week that examines a legal strategy drugmakers use to defend themselves against patient lawsuits, according to STAT.

Hospital nurses regularly dispose of unused medicines in sinks or toilets, but hospital leaders may want to reconsider this practice to avoid harm from dangerous substances entering the water supply, CNN reports.

At least three dozen drugmakers started the year by raising the prices of hundreds of medicines by an average of 6.3 percent, according to The Wall Street Journal.

A federal judge blocked a Trump administration rule that reduces payments to hospitals under the 340B drug discount program, ruling Dec. 28 that the government overstepped its authority in its effort to address high prescription medication costs, according to STAT.

Americans pay up to 80 percent more for biosimilars — or copycat versions of biologic drugs —  than their European counterparts, according to the San Francisco Chronicle.

As disruptors continue to push into the healthcare arena and pressure accumulates to reduce drug prices, pharmaceutical companies are taking steps to remain competitive and enhance their drug pipelines.